Boston-based Mwyngil Therapeutics reported preclinical proof-of-concept data for its GPR75 inverse agonist obesity program, with lead oral compounds producing up to 25% body weight reduction in diet-induced obesity mouse models while preserving lean mass — potentially offering a differentiated mechanism from the dominant GLP-1 receptor agonist class in cardiometabolic disease treatment.
The data appears to be one of the first public in vivo efficacy datasets for a small-molecule GPR75 obesity program, a genetically validated target that has attracted industry interest since human loss-of-function variants were linked to protection against obesity in 2021.
The data, generated in a 4-week study, also demonstrated broad metabolic improvements across glycemic, inflammatory, and hepatic parameters, supporting the company's thesis that GPR75 modulation addresses systemic metabolic regulation rather than appetite suppression alone.
The results matter to the obesity drug development field because lean mass preservation during weight loss has emerged as a defining competitive dimension. Approved GLP-1 receptor agonists, including Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide), are associated with an estimated 20%–40% loss of lean mass as a proportion of total weight lost — a concern that has intensified as longer treatment durations become standard and as the patient population broadens beyond those with severe obesity. Mwyngil's GPR75 program, by contrast, demonstrated lean mass preservation across all tested doses alongside a 33%–50% reduction in fat rate and up to 1.5-fold reduction in epididymal white adipose tissue. These are animal data, and cross-trial comparisons with clinical incretin programs are not meaningful at this stage, but the preclinical body composition profile is the central differentiation claim the company is advancing.
The GPR75 inverse agonist mechanism and rationale
GPR75 is an orphan G-protein-coupled receptor expressed in hypothalamic neurons, adipose tissue, liver, kidney, and vascular endothelium. Mwyngil's compounds are designed as selective oral allosteric inverse agonists — molecules that suppress constitutive receptor activity rather than simply blocking agonist binding. The target's genetic validation is unusually strong: a study involving approximately 640,000 individuals identified loss-of-function variants in GPR75 associated with lower BMI and reduced obesity risk, and GPR75 knockout mice showed substantially reduced susceptibility to diet-induced weight gain. This positions GPR75 alongside a small number of obesity targets with direct human genetic support, a bar that GLP-1 receptor programs met early and that the field increasingly demands of new entrants.